Question 9643 — pharmacy and medicines

Summary

Ms. Sophie Errante draws the attention of the Minister to the Minister of Labor, Health, Solidarity and Families, responsible for health and access to care, to the problem of access to Repatha (evolocumab), from the American laboratory Amgen. For several weeks, many patients and healthcare professionals have reported increasing difficulties in obtaining this medication in pharmacies, thus compromising continuity. care and exposing patients to increased risks of serious cardiovascular events. The ANSM has in fact been reporting supply tensions since March 2025, with no normal delivery date to date. This major and innovative hypocholesterolemic drug is prescribed in particular to patients at high cardiovascular risk who cannot achieve their LDL-cholesterol goals with traditional treatments, in order to lower their cholesterol levels. Without treatment, the risks for these patients of having another heart attack are very real, especially since there are, at present, no alternatives on the market to this one. As a reminder, cardiovascular diseases and their complications are the second cause of death in France with, each year, 140,000 deaths in France and 1.2 million hospitalizations among adults. The difficulties access, or even shortage, of Repatha therefore gives rise to serious concern among health professionals and the patients concerned. This also raises legitimate questions about the capacity of the health system to guarantee access to innovative and essential treatments as well as the mechanisms for anticipating and managing shortages in the supply of essential medicines. Consequently, she wishes to know the measures that the Government intends to take in order to quickly resolve this shortage and restore the normal supply of Repatha throughout the territory, to strengthen transparency on the causes of this rupture, particularly with regard to the responsibilities of each person and to prevent the recurrence of such situations for critical treatments by implementing a more robust chain security policy supply.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.